Brainsway (NASDAQ:BWAY) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Brainsway (NASDAQ:BWAY) from a buy rating to a hold rating in a research note released on Saturday morning.

Several other analysts have also weighed in on BWAY. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Brainsway in a research note on Tuesday, November 11th. HC Wainwright increased their target price on shares of Brainsway from $17.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Northland Securities raised their price target on shares of Brainsway from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday, November 12th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Brainsway Trading Down 3.7%

Shares of BWAY opened at $15.18 on Friday. The company’s fifty day simple moving average is $15.81 and its 200 day simple moving average is $13.37. Brainsway has a 1-year low of $7.84 and a 1-year high of $17.92. The company has a market cap of $296.92 million, a price-to-earnings ratio of 50.60 and a beta of 1.22.

Brainsway (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, November 11th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.03). Brainsway had a net margin of 12.73% and a return on equity of 9.46%. The company had revenue of $13.51 million during the quarter, compared to the consensus estimate of $13.04 million. Brainsway has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Brainsway will post 0.08 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC boosted its holdings in Brainsway by 7.3% in the first quarter. ARK Investment Management LLC now owns 188,328 shares of the company’s stock worth $1,783,000 after acquiring an additional 12,740 shares in the last quarter. Eagle Global Advisors LLC bought a new stake in shares of Brainsway during the first quarter valued at approximately $590,000. Trexquant Investment LP acquired a new position in shares of Brainsway during the first quarter worth approximately $129,000. NewEdge Advisors LLC lifted its holdings in shares of Brainsway by 61.5% in the 1st quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock worth $188,000 after purchasing an additional 7,549 shares in the last quarter. Finally, Huntleigh Advisors Inc. lifted its holdings in shares of Brainsway by 5.7% in the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after purchasing an additional 4,143 shares in the last quarter. 30.11% of the stock is owned by institutional investors.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.